FDA clears mAbxience and Amneal’s denosumab biosimilars: What it means for the bone health and oncology market

The U.S. Food and Drug Administration has approved Boncresa (denosumab-mobz) and Oziltus (denosumab-mobz), two biosimilars referencing Prolia and XGEVA, respectively. The dual clearance, submitted under the Biologics Licensing Application pathway by mAbxience and commercialized exclusively in the U.S. by Amneal Pharmaceuticals (NASDAQ: AMRX), marks a strategic entry into the high-value biologics market for osteoporosis and oncology-related bone disorders.

These denosumab biosimilars represent not only a cost-saving alternative for patients and payers, but also an expansion milestone for mAbxience’s global manufacturing footprint and Amneal’s ambitions to grow its biosimilars franchise. The approvals solidify Amneal’s fifth biosimilar in its U.S. portfolio and demonstrate regulatory trust in mAbxience’s manufacturing platform, which spans GMP-certified sites in Europe and South America.

Why FDA approval of Amneal’s Boncresa and Oziltus signals a maturing U.S. biosimilars market

The significance of this dual approval lies not just in the substitution opportunity for Prolia and XGEVA, both blockbuster drugs owned by Amgen, but in the clear signal it sends about the FDA’s increasing comfort with biosimilar entrants in complex monoclonal antibody categories.

Denosumab is a fully human monoclonal antibody that inhibits RANKL and is used to prevent bone complications in cancer patients as well as to treat osteoporosis in postmenopausal women. With Prolia and XGEVA earning Amgen nearly $4 billion combined in 2024 U.S. sales, biosimilar competition has long been anticipated. Until now, however, no biosimilar to denosumab had been approved by the FDA.

What makes this milestone particularly notable is that both Boncresa and Oziltus are based on the same active molecule and were approved concurrently for their distinct reference indications—Prolia in osteoporosis, and XGEVA in oncology. This is one of the few biosimilar launches to pursue the dual-path approach for both conditions simultaneously, setting a precedent for future filings in crossover therapeutic areas.

How does the mAbxience–Amneal partnership structure impact market rollout and commercial execution?

Under the agreement, mAbxience retains development and manufacturing responsibilities while Amneal holds exclusive commercialization rights in the United States. This B2B-style division of roles enables Amneal to leverage its U.S. market access expertise, regulatory infrastructure, and specialty sales channels while minimizing its upstream manufacturing risk.

For mAbxience, the FDA approval validates its vertically integrated CDMO strategy and enhances its B2B exportability. The company already has supply partnerships in over 100 markets and operates three major biologics manufacturing facilities. Gaining FDA approval for a high-bar molecule like denosumab reinforces its standing as a go-to biosimilar development partner for other pharma and biotech players.

The dual-entity model is becoming more common as U.S.-based companies seek de-risked entry into complex biologics while international players look to U.S. market penetration without building local salesforces.

What regulatory and clinical standards did Boncresa and Oziltus need to meet?

Given the complexity of denosumab’s mechanism of action and its risk profile, which includes boxed warnings for severe hypocalcemia and potential teratogenicity, biosimilar versions must show a high level of analytical and clinical similarity. The FDA’s abbreviated pathway still requires pharmacokinetic, pharmacodynamic, and safety studies to ensure no clinically meaningful differences from the reference product.

Both biosimilars carry the same boxed and safety warnings as their originators. For Boncresa (Prolia reference), risks include musculoskeletal pain, hypocalcemia, and urinary tract issues. For Oziltus (XGEVA reference), adverse events such as fatigue, nausea, and osteonecrosis of the jaw must be carefully managed, particularly in cancer patients with bone metastases.

Given these safety considerations, both biosimilars are administered by healthcare professionals rather than self-administered, preserving clinician oversight in dosing and follow-up.

Could payer adoption and clinician trust affect biosimilar uptake in bone health?

Payer appetite for biosimilars is high, especially for blockbuster molecules with limited generic competition. However, uptake often hinges on formulary inclusion, physician confidence, and incentives for switching. The bone health segment, particularly osteoporosis in elderly postmenopausal women, requires additional effort in education, particularly regarding long-term safety, interchangeability, and the role of calcium monitoring.

For oncology use cases, payer alignment may be faster given the cost burden of XGEVA and the relatively controlled setting of oncology clinics. Still, risk of osteonecrosis and the presence of alternatives like bisphosphonates may create switching friction.

With Amneal’s positioning in Affordable Medicines, formulary wins and specialty pharmacy access will be essential. Whether Boncresa and Oziltus gain automatic substitution or require explicit prescribing will vary by state and institution, affecting volume ramp.

What’s the commercial outlook for Amneal’s biosimilar strategy after denosumab?

Amneal has now commercialized five biosimilars in the United States, with denosumab joining pegfilgrastim, trastuzumab, bevacizumab, and filgrastim products. The company sees biosimilars as a long-term growth engine, particularly as biologics account for over 40% of U.S. drug spend but remain cost-restrictive in many therapeutic areas.

This approval strengthens Amneal’s position in both its Affordable Medicines and Specialty segments. In the former, biosimilars help reduce system-wide costs; in the latter, they support access to branded-like therapies in areas like CNS and endocrinology.

Investor sentiment has been cautiously optimistic about Amneal’s biosimilars push, but competitive intensity and margin compression remain concerns. By partnering with mAbxience, a contract development and manufacturing organization with global reach and regulatory credentials, Amneal mitigates capex and operational risk while extending its product breadth.

How does this impact mAbxience’s strategic positioning in the global CDMO and biosimilars landscape?

For mAbxience, the dual FDA approval enhances its credibility not just as a biosimilar developer but as a global CDMO partner. The company’s multiregional GMP sites and regulatory track record now include denosumab, a difficult to manufacture monoclonal antibody with high clinical relevance.

The Fresenius Kabi–Insud Pharma–mAbxience corporate structure gives it access to both development capital and commercial relationships, allowing it to play a modular role depending on the geography. Its ability to manufacture complex biologics for regulated markets such as the U.S. and EU makes it a prime partner for biosimilar co-development, especially for firms looking to avoid in-house biologics buildouts.

The successful U.S. approval also improves mAbxience’s visibility in the competitive CDMO bidding market, potentially unlocking more contracts with large and mid-cap pharma companies in Europe, Latin America, and Asia.

Key takeaways on what the FDA’s denosumab biosimilar approvals mean for Amneal, mAbxience, and the U.S. biologics market

• The FDA approved Boncresa and Oziltus, biosimilars referencing Prolia and XGEVA, marking the first denosumab biosimilar clearances in the U.S.

• Amneal Pharmaceuticals now has five biosimilars in its commercial portfolio, strengthening its Affordable Medicines segment.

• mAbxience’s FDA success reinforces its position as a global CDMO with validated high-bar biologics manufacturing capacity.

• Dual biosimilar approval for osteoporosis and oncology indications showcases the FDA’s evolving confidence in biosimilar pathways.

• Payer adoption will be critical to commercial uptake, with oncology channels likely to move faster than primary care osteoporosis segments.

• Regulatory-compliant manufacturing in Europe and South America offers mAbxience supply chain optionality and cost efficiency.

• The denosumab win could attract new co-development deals for mAbxience from U.S. and EU-based biopharma firms.

• Amneal’s biosimilar expansion helps diversify revenue as it competes in both cost-sensitive and specialty therapeutic categories.